Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis — Gordon R. Bernard (2001) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
Shared by
Jean Louis Vincent
Université Libre de Bruxelles
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
Article
2001
en
Authors
+8 more
GB
Gordon R. Bernard
Jean Louis Vincent
Université Libre de Bruxelles
PL
Pierre‐François Laterre
Abstract
1 min read
Treatment with drotrecogin alfa activated significantly reduces mortality in patients with severe sepsis and may be associated with an increased risk of bleeding.
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2006
Drotrecogin alfa (activated) in the treatment of severe sepsis
Jean Louis Vincent
Article
2002
Drotrecogin alfa: a new approach in the treatment of severe sepsis
Jean Louis Vincent
Article
2007
Drotrecogin Alfa (Activated) in the Treatment of Severe Sepsis
Jean Louis Vincent
Letter
2002
Activated Protein C for Severe Sepsis
E. Wesley Ely
,
Gordon R. Bernard
,
Jean Louis Vincent
Article
2007
Drotrecogin alfa (activated): the treatment for severe sepsis?
Jean Louis Vincent
Discussion(0)
No comments yet. Be the first to comment.